What Happened?
Cambridge, MA-based Nuvalent Appointed James Porter as Chief Executive Officer
About the Company
Nuvalent is creating precisely targeted therapies for patients with cancer designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in structure-based design, Nuvalent develops innovative small molecules with exquisite target selectivity to overcome resistance, minimize adverse events, and drive more durable responses. Nuvalent is advancing a robust pipeline with parallel lead programs in ROS1-positive and ALK-positive NSCLC, along with multiple discovery-stage research programs.
About the Person
James Porter is Chief Executive Officer at Nuvalent. Previously, James held various senior HR leadership roles in the industry.
Info Source
News
Short Profile